The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Congress 2022 | Management of patients with PV who are intolerant to interferon and who develop post-polycythemic MF
Richard Silver, MD, Weill Cornell Medical College, New York, NY, discusses the management of patients with polycythemia vera (PV) who are intolerant to treatment with interferon (IFN) and who develop post-polycythemic myelofibrosis (MF), commenting on the utility of a potential marker to predict outcomes and response to treatment. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
